These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 16707463)

  • 21. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
    Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A; McDonnell TJ; Meyn RE
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.
    Shankar S; Singh TR; Chen X; Thakkar H; Firnin J; Srivastava RK
    Int J Oncol; 2004 May; 24(5):1133-40. PubMed ID: 15067334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and antitumor effects of TRAIL in human cholangiocarcinoma.
    Tanaka S; Sugimachi K; Shirabe K; Shimada M; Wands JR
    Hepatology; 2000 Sep; 32(3):523-7. PubMed ID: 10960444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL; Zou WY; Song LH; Wei W
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
    Wahl H; Tan L; Griffith K; Choi M; Liu JR
    Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
    Frese S; Pirnia F; Miescher D; Krajewski S; Borner MM; Reed JC; Schmid RA
    Oncogene; 2003 Aug; 22(35):5427-35. PubMed ID: 12934102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.
    Roth W; Isenmann S; Naumann U; Kügler S; Bähr M; Dichgans J; Ashkenazi A; Weller M
    Biochem Biophys Res Commun; 1999 Nov; 265(2):479-83. PubMed ID: 10558893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
    Arizono Y; Yoshikawa H; Naganuma H; Hamada Y; Nakajima Y; Tasaka K
    Br J Cancer; 2003 Jan; 88(2):298-306. PubMed ID: 12610517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells.
    Sridhar S; Ali AA; Liang Y; El Etreby MF; Lewis RW; Kumar MV
    Cancer Res; 2001 Oct; 61(19):7179-83. PubMed ID: 11585752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice.
    Secchiero P; Candido R; Corallini F; Zacchigna S; Toffoli B; Rimondi E; Fabris B; Giacca M; Zauli G
    Circulation; 2006 Oct; 114(14):1522-30. PubMed ID: 17000905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting death receptors in cancer with Apo2L/TRAIL.
    Kelley SK; Ashkenazi A
    Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.
    Nakshatri H; Rice SE; Bhat-Nakshatri P
    Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2.
    Klüttermann K; Banning U; Kachel M; Krause C; Körholz D; Mauz-Körholz C
    Anticancer Res; 2006; 26(1A):351-6. PubMed ID: 16475717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.